Clinical Trial Update: A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 safety and dose-ranging study evaluating three oral doses of TCH-346 in patients with Amyotrophic Lateral Sclerosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• TCH-346 (TCH-346)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED